Roche Holding AG/Chugai Pharmaceutical Co., Ltd.’s subcutaneous anti-C5 antibody crovalimab has received its global-first approval, in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients 12 years of age and above not been previously treated with complement inhibitors.
Crovalimab Gets First Nod In China For PNH, Fiercer Global Competition Awaits
The anti-C5 inhibitor sets an example of swift global trial and approval in China while fiercer competition awaits in the US, Europe and Japan.
